BiotechTube

azathioprine + sirolimus

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Delayed Graft Function

Conditions

Delayed Graft Function, Acute Graft Rejection

Trial Timeline

Apr 1, 2002 → Aug 1, 2011

NCT ID
NCT00321906

About azathioprine + sirolimus

azathioprine + sirolimus is a approved stage product being developed by Astellas Pharma for Delayed Graft Function. The current trial status is completed. This product is registered under clinical trial identifier NCT00321906. Target conditions include Delayed Graft Function, Acute Graft Rejection.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00321906ApprovedCompleted

Competing Products

8 competing products in Delayed Graft Function

See all competitors
ProductCompanyStageHype Score
Lemborexant + PlaceboEisaiApproved
85
Belatacept + EverolimusBristol Myers SquibbPhase 1
32
Belatacept + Calcineurin InhibitorBristol Myers SquibbPhase 2
51
ARGX-117ArgenxPhase 2
49
BG9418 (interferon beta-1a)BiogenPre-clinical
20
Desflurane + PropofolBaxterApproved
82
PegcetacoplanApellis PharmaceuticalsPhase 3
72
TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + DiluentTonix PharmaceuticalsPhase 1
25

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85